Introduction
============

A landmark in the battle against viral infectious diseases was made in 1798 when Jenner first inoculated humans against smallpox with the less virulent cowpox. For about two centuries since then, humans relied almost exclusively on vaccines for protection against viruses. Only in the recent years, new strategies for controlling viral infectious diseases have emerged, which have so far led to a couple of viral prophylaxis/therapeutics on the market. These strategies are fundamentally different from vaccines in that they attempt to directly interrupt viral infectious life cycle at molecular level by using proteins or oligonucleotides. To differentiate them from the conventional vaccines that prevent viral infection by boosting immune system, we refer the new antiviral approaches as \"Biochemical Prevention and Treatment\" (see figure [1](#F1){ref-type="fig"}). Biochemical Prevention and Treatment, as an alternative to vaccines and chemical compound based antiviral drugs, may prove to be particularly valuable in the areas where vaccines and/or chemical drugs can not be generated or have not been successful in human, including diseases caused by some common pathogenic viruses, such as HIV, hepatitis C virus (HCV), RSV and human rhinovirus (HRV). In this review, we will discuss various molecular intervention approaches.

![**Targets of different Biochemical Prevention and Treatment strategies**. Antibodies (Ab) or soluble receptors (Rc) can inhibit the viral entry. Antisense oligonucleotides (AS-ONs), ribozymes (Rz) or siRNA (SI) pair with their complementary target genomic DNA, RNA or mRNA. AS-ONs can block recombination, transcription, translation of the mRNA or induce its degradation by RNaseH. Rz possess catalytic activity and cleave their targets. SiRNAs (SI) induce degradation of the target mRNA via RNA-induced silencing complex (RISC).](1743-422X-1-12-1){#F1}

1. Biochemical Prevention and Treatment via Protein targeting
-------------------------------------------------------------

Among the biochemical therapeutics currently in clinical trials, the majority consists of monoclonal antibodies (MAbs). Soluble receptor drug candidates have gradually lost favor over the past several years due to issues relating to low potency and cost. Peptide-based drug candidates are limited by insufficient efficacy and unfavorable pharmacokinetics. MAbs have increasingly gained favor in large part because of the development of chimeric, humanized, and human antibodies have reduced the immunogenicity of antibody therapies. The MAbs that are currently in clinical trials for viral infection prophylaxis and treatment are listed in Table [1](#T1){ref-type="table"}.

###### 

Monoclonal Antibodies in Clinical Trials

  **Product**              **Company**                                 **Disease**                   **Status**
  ------------------------ ------------------------------------------- ----------------------------- ------------------
  MEDI-501                 MedImmune                                   Genital Warts HPV             II
  Nabi-HB                  Nabi Biopharmaceuticals                     Hepatitis B                   Market
  Ostavir                  Protein Design Labs                         Hepatitis B                   II
  XTL-002                  XTL Biopharmaceuticals Ltd.                 Hepatitis C                   I
  Civacir                  Nabi Biopharmaceuticals                     Hepatitis C                   I/II
  1F7 Antibody             Immune Network Ltd.                         Hepatitis C, HIV/AIDS         Preclinical
  PRO 140                  Progenics Pharmaceuticals                   HIV/AIDS                      Preclinical
  hNM01                    AbNovo Inc., Immune Network Ltd.            HIV/AIDS                      I
  PRO 367                  Roche Holding Progenics Pharmaceuticals     HIV/AIDS                      I/II
  TNX-355                  Tanox, Inc., Biogen, Inc. (Massachusetts)   HIV/AIDS                      I
  OraQuick HIV-1           OraSure Technologies, Inc.                  HIV/AIDS                      Market
  Cytolin                  CytoDyn Amerimmune Pharmaceuticals, Inc.    HIV/AIDS                      I/II
  Tipranavir               TIPRANAVIR                                  HIV/AIDS                      III
  HXB                      AAI International, AnaaiPharma Company      Herpes Simplex Virus type 2   Preclinical
  MEDI-491                 MedImmune                                   Human B19 parvovirus          I
  Synagis™ (Palivizumab)   MedImmune                                   Respiratory Syncytial Virus   Approved in 1998
  Numax                    MedImmune                                   Respiratory Syncytial Virus   Preclinical
  INS37217 Intranasal      Inspire Pharmaceuticals                     Rhinovirus (common cold)      II

### Biochemical Prevention and Treatment of Respiratory Syncytial Virus Infection

The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants and young children producing bronchiolitis and pneumonia worldwide. RSV infection leads to more than 90,000 hospitalizations and a 2% mortality rate among infants nationwide \[[@B2]-[@B5]\]. Approximately two-thirds of infants are infected with RSV during the first year of life and approximately 95% of children test seropositive for RSV by the age of two \[[@B6]\]. Unfortunately, even natural RSV infection produces limited immunity at best. In fact, an inactivated RSV vaccine paradoxically resulted in more severe disease instead of protection \[[@B7]\].

The most successful approach to date has been Biochemical Prevention and Treatment with anti-viral antibodies. In 1996, RespiGam™ (respiratory syncytial virus immune globulin or RSV-IG) became available for use in children less than two years of age with high-risk factors \[[@B8]-[@B10]\]. The use of RespiGam™ was largely supplanted with the approval of Synagis™ (Palivizumab) in 1998. Palivizumab is an IgG1 MAb administered IM monthly that selectively binds to the RSV surface glycoprotein F \[[@B1],[@B51]\]. The drug specifically inhibits RSV replication by preventing the virus from fusing with the respiratory endothelial cell membrane. Palivizumab has been shown to reduce the rate of hospitalization of at-risk infants by about 55% in clinical studies and now serves as the primary medical means of RSV prevention \[[@B11]-[@B13]\].

### Prevention of Human Rhinovirus infections

Human rhinovirus (HRV) causes over 80% of the common cold in the fall \[[@B14]\]. Developing vaccines against HRV is unfeasible because HRVs have at least 115 antigenically distinct serotypes \[[@B15],[@B16]\]. One of the proven methods to prevent and inhibit viral infections is to block host cell receptors that are used by viruses to gain cell entry. Receptor blockage is commonly achieved via application of MAbs that bind to specific epitopes on the receptor molecules. A plethora of *in vitro*studies have reported effective viral inhibition by receptor-blocking MAbs. However, these works have not yielded yet any approved drug on the market.

In HRV infection, about 90% of HRV serotypes utilize a single cell surface receptor exclusively, which is the intercellular adhesion molecule-1 (ICAM-1), for viral attachment and subsequent viral entry \[[@B17],[@B18]\]. As such, ICAM-1 has become a very promising target for biochemical prevention. A receptor blocking approach has shown that the soluble ICAM-1 and an anti-ICAM-1 monoclonal antibody, Mab 1A6, could prevent infections by a broad spectrum of rhinovirus serotypes in human cells *in vitro*\[[@B19]-[@B21]\]. Administration of soluble ICAM-1 and MAbs in human clinical trials had indeed achieved reduction in symptoms, but did not prevent the incidence of the disease \[[@B22]-[@B24]\]. For the MAbs, the limited efficacy is most likely due to its low functional affinity (or avidity) for ICAM-1 when compared to that of the multivalent HRV particles \[[@B25]\].

High avidity is achieved by multivalency. To improve avidity of HRV receptor blocking antibody, a novel tetravalent recombinant antibody, CFY196, has been generated against ICAM-1 \[[@B26]\]. CFY196 is composed of Fab fragment of a humanized version of MAb 1A6 fused with a linker derived from human immunoglobulin D (IgD) hinge and a tetramerization domain derived from the coiled-coil sequence of human transcription factor ATFα. CFY196 is expressed in bacteria and purified as a homogenous tetrameric molecular complex. CFY196 exhibited almost two-orders-of-magnitude improvement in functional affinity compared with its bivalent counterpart based on the kinetic parameters measured by BIAcore analysis. Such kinetic improvement also directly leads to functional superiorities of CFY196. In *in vitro*assays, CFY196 consistently and significantly outpaced the best commercial anti-ICAM-1 MAbs in preventing HRV infection as measured by reduction of cytopathic effects and HRV viral titers \[[@B26]\]. The preclinical findings of CFY196 bode well its efficacy in human since MAb 1A6, from which CFY196 is derived, has already exhibited positive effects in a human trial. Moreover, to prevent possible immunogenicity, CFY196 is humanized \[[@B27]\]. Further pre-clinical and clinical development of CFY196 is warranted to fully evaluate its potential as a prophylaxis and therapeutics for the HRV induced common colds.

2. Biochemical Prevention and Treatment via targeting on viral mRNA
-------------------------------------------------------------------

Targeting viral mRNA is one of the most active areas of research and development. Several strategies have emerged over the years and are being tested pre-clinically and clinically. They include: antisense-oligonucleotides (AS-ONs), ribozymes, and recently, RNA interference (RNAi). All these strategies share the features of conceptual simplicity, straightforward drug design and quick route to identify drug leads. However, the challenges have been to improve potency, pharmacokinetics and, most importantly, intracellular delivery of the drug candidates. As the oldest strategy, AS-ON technology has produced to date one drug in the market place, Vitravene^®^. A number of clinical trials of drug candidates from these technologies are currently ongoing.

### Antisense-oligonucleotides

Antisense-oligonucleotides (AS-ONs) are short synthetic oligonucleotides that form complementary pair with specific viral mRNA targets. AS-ONs inhibit viral protein production by both blocking viral mRNA translation and triggering its degradation. Since the discovery of viral inhibition effect of AS-ONs by Zamecnik and Stephenson in 1978 \[[@B28]\], antisense technology has been developed as a powerful tool for target validation and therapeutic purposes.

Vitravene is the first AS-ON based drug approved by FDA. Vitravene, or fomivirsen sodium, is a 21-base phosphorothioate oligodeoxynucleotide complementary to the messenger RNA of the major immediate-early region proteins of human cytomegalovirus, and is a potent and selective antiviral agent for cytomegalovirus retinitis, a herpes-like eye disease that afflicts the immune-suppressed \[[@B29],[@B30]\]. A number of clinical trials as well as one approved therapy based on AS-ON technologies are summarized in Table [2](#T2){ref-type="table"}.

###### 

Clinical trials and an approved therapy based on AS-ON technologies \[31-33\].

  **Product**               **Company**                  **Target**                      **Disease**                                       **Chemistry**    **Status**
  ------------------------- ---------------------------- ------------------------------- ------------------------------------------------- ---------------- ------------------
  Vitravene (Fomivirsen)    ISIS Pharmaceuticals         CMV IE2                         CMV retinitis                                     PS DNA           Approved in 1998
  Affinitac (ISIS 3521)     ISIS                         PKC-α                           Cancer                                            PS DNA           Phase III
  Genasense                 Genta                        Bcl2                            Cancer                                            PS DNA           Phase III
  Alicaforsen (ISIS 2302)   ISIS                         ICAM-1                          Psoriasis, Crohn\'s disease, Ulcerative colitis   PS DNA           Phase II/III
  ISIS 14803                ISIS                         Antiviral                       Hepatitis C                                       PS DNA           Phase II
  ISIS 2503                 ISIS                         H-ras                           Cancer                                            PS DNA           Phase II
  MG98                      Methylgene                   DNA methyl transferase          Solid tumors                                      PS DNA           Phase II
  EPI-2010                  EpiGenesis Pharmaceuticals   Adenosine A1 receptor           Asthma                                            PS DNA           Phase II
  GTI 2040                  Lorus Therapeutics           Ribonucleotide reductase (R2)   Cancer                                            PS DNA           Phase II
  ISIS 104838               ISIS                         TNFα                            Rheumatoid Arthritis, Psoriasis                   2nd generation   Phase II
  Avi4126                   AVI BioPharma                c-myc                           Restenosis, cancer, Polycystic kidney disease     3rd generation   Phase I/II
  Gem231                    Hybridon                     PKA RIα                         Solid tumors                                      2nd generation   Phase I/II
  Gem92                     Hybridon                     HIV gag                         AIDS                                              2nd generation   Phase I
  GTI 2051                  Lorus Therapeutics           Ribonucleotide reductase (R1)   Cancer                                            PS DNA           Phase I
  Avi4557                   AVI BioPharma                CYP3A4                          Metabolic redirection of approved drugs           3rd generation   Phase I

Phosphorothioate (PS) oligodeoxynucleotides are the \'*first generation*\' DNA analogs. The \'*second generation*\' ONs contain nucleotides with alkyl modifications at the 2\' position of the ribose. They are less toxic than PS-DNAs and have a slightly enhanced affinity. DNA and RNA analogs with modified phosphate linkages, or different sugar residues substituting the furanose ring have been referred as \'*third generation*\' \[[@B34]\]. For instance, peptide nucleic acids and their analogs display superior sequence specificity and are resistant to nuclease degradation. These third generation AS-ON have limited non-specific interactions with other genes and, therefore, have shown great potentials in clinical trials.

### Ribozymes

Ribozymes (Rz) are catalytically active ONs that both bind and cleave target RNAs. They were discovered after the AS-ON technology. Initial findings on ribozymes raised the hope that they may offer a more potent alternative to AS-ONs. Many cell based and animal tests have performed on anti-viral effects of ribozymes, including HIV, hepatitis B, hepatitis C, influenza, etc. Results from these tests have shown that ribozymes are promising viral inhibitors \[[@B35]-[@B38]\]. However, further progress in the field has been hampered by difficulties to achieve satisfactory potency and efficient intracellular delivery of ribozymes in vivo. HEPTAZYME is a modified ribozyme that cleaves the internal ribosome entry site of the Hepatitis C virus. The Rz was demonstrated to inhibit viral replication up to 90% in cell culture \[[@B39]\]. HEPTAZYME was tested in a Phase II clinical trial, but was later withdrawn from further clinical trials due to insufficient efficacy. So far, there is no anti-viral ribozymes that are being actively tested in advanced clinical trials.

### RNA Interference (RNAi)

RNA interference, or RNAi, is the inhibition of expression of specific genes by double-stranded RNAs (dsRNAs). It is becoming the method of choice to knockdown gene expression rapidly and robustly in mammalian cells. Comparing to the traditional antisense method, RNAi technology has the advantage of significantly enhanced potency; therefore, only lower concentrations may be needed to achieve same level of gene knockdown. RNAi gained rapid acceptance by researchers after Tuschl and coworkers discovered that *in vitro*synthesized small interfering RNAs (siRNAs) of 21 to 23 nucleotides in length can effectively silence targeted genes in mammalian cells without triggering interferon production \[[@B40],[@B41]\]. In mammalian cells, the level of gene inhibition mediated by siRNA routinely reaches an impressive 90% \[[@B42]\].

Several initial studies, which test the potential application of synthetic siRNAs as antiviral agents, have shown very promising results. To date, RNAi has been used effectively to inhibit the replication of several different pathogenic viruses in culture, including: RSV (respiratory syncytial virus) \[[@B43]\], influenza virus \[[@B44]\], poliovirus \[[@B45]\] and HIV-1 \[[@B46]-[@B48]\]. In the case of HIV-1, several specific mRNAs have been successfully targeted for siRNA-mediated silencing, including those that encode Gag, Pol, Vif and the small regulatory proteins Tat and Rev. These studies show that RNAi can effectively trigger the degradation of not only viral mRNAs, but also genomic RNAs at both the pre- and post-integration stages of the viral lifecycle. In addition to targeting viruses directly, alternative strategies have employed siRNAs that silence the expression of essential host factors including Tsg101, required for vacuolar sorting and efficient budding of HIV-1 progeny \[[@B49]\], and the chemokine receptor CCR5, required as a co-receptor for HIV-1 cell entry \[[@B50]\].

Conclusions
===========

Currently, our understanding of the biological mechanisms underlying RNAi lags behind the movement to apply this technology to human diseases such as viral infections. Some major technical hurdles need to be overcome before siRNA-based anti-viral prophylaxis and treatments move into the clinics. Especially, intracellular delivery of siRNA needs to be greatly improved. The next few years of research will indicate whether RNAi technology will realize its potential as the next wave of Biochemical Prevention and Treatment.
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